Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Screening Performance and Costs of Different Strategies in Prenatal Screening for Trisomy 21

14 Apr 2015

Abstract excerpt

Objective: Cell-free fetal DNA (cffDNA) testing has opened new options in prenatal screening for trisomy 21. Due to the higher costs of cffDNA testing there is an ongoing debate on how to combine different screening strategies. Methods: For this study, a model-based approach was used to evaluate all births in Germany in 2012 together with the percentage of euploid and trisomic pregnancies. Detection rates (DR),...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Parvovirus B19 Infection Studies
Share to Prenatal Screening and Diagnostics

Source

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Identifiers

PMID: 25914417
DOI: 10.1055/s-0035-1545885

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Screening Performance and Costs of Different Strategies in Prenatal Screening for Trisomy 21PMID 25914417Read ↗

The contingent use of cell-free fetal DNA for prenatal screening of trisomies 21, 18, 13 in pregnant women within a national health service: A budget impact analysisSemantic proximity Read ↗

Combined First Trimester Screening and Cell-Free Fetal DNA – “Next Generation Screening”Semantic proximity Read ↗

Accuracy of first‐trimester combined test in screening for trisomies 21, 18 and 13Semantic proximity Read ↗

Screening for trisomies 21, 18 and 13 by cell‐free <scp>DNA</scp> analysis of maternal blood at 10–11 weeks' gestation and the combined test at 11–13 weeksSemantic proximity Read ↗

Screening for Chromosomal Abnormalities by First Trimester Combined Screening and Noninvasive Prenatal TestingSemantic proximity Read ↗

First‐trimester screening for trisomy 21 in Denmark: implications for detection and birth rates of trisomy 18 and trisomy 13Semantic proximity Read ↗

First‐trimester contingent screening for trisomies 21, 18 and 13 by fetal nuchal translucency and ductus venosus flow and maternal blood cell‐free DNA testingSemantic proximity Read ↗

Maternal age‐ and gestation‐specific risk for trisomy 21Semantic proximity Read ↗

The value of combined detailed first- trimester ultrasound– biochemical analysis for screening fetal aneuploidy in the era of non-invasive prenatal testingSemantic proximity Read ↗

Contingent first‐trimester screening for aneuploidies with cell‐free DNA in a Danish clinical settingSemantic proximity Read ↗

An Economic Analysis of Cell-Free DNA Non-Invasive Prenatal Testing in the US General Pregnancy PopulationSemantic proximity Read ↗

Prenatal diagnostic testing and atypical chromosome abnormalities following combined first‐trimester screening: implications for contingent models of non‐invasive prenatal testingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.